{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T09:26:07Z","timestamp":1792315567876,"version":"4.4.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.phrs.2023.106967","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T03:08:00Z","timestamp":1697771280000},"page":"106967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Clinical pharmacology facing the real-world setting: Pharmacovigilance, pharmacoepidemiology and the economic evaluation of drugs"],"prefix":"10.1016","volume":"197","author":[{"given":"Antonia","family":"Agust\u00ed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Cereza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"de Abajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Maci\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Sacrist\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.phrs.2023.106967_bib1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/clpt.2011.345","article-title":"Adaptive licensing: taking the next step in the evolution of drug approval","volume":"91","author":"Eichler","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2023.106967_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cpt.2465","article-title":"The \"coming of age\" of real-world evidence in drug development and regulation","volume":"111","author":"Honig","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2023.106967_bib3","series-title":"Los primeros 25 a\u00f1os del Sistema Espa\u00f1ol de Farmacovigilancia de Medicamentos de Uso Humano","first-page":"25","article-title":"El programa de la tarjeta amarilla en Espa\u00f1a: sus or\u00edgenes","author":"Capell\u00e0","year":"2010"},{"key":"10.1016\/j.phrs.2023.106967_bib4","series-title":"Mann\u2019s Pharmacovigilance","first-page":"217","article-title":"Pharmacovigilance in Spain","author":"Montero","year":"2014"},{"issue":"4","key":"10.1016\/j.phrs.2023.106967_bib5","first-page":"126","article-title":"Cough caused by angiotensin-converting enzyme inhibitors. A series of cases collected by spontaneous notification of adverse reactions","volume":"96","author":"Capell\u00e0","year":"1991","journal-title":"Med. Clin. (Barc. )"},{"key":"10.1016\/j.phrs.2023.106967_bib6","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1183\/09031936.00092812","article-title":"Nightmares induced by montelukast in children and adults","volume":"40","author":"Cereza","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"6865","key":"10.1016\/j.phrs.2023.106967_bib7","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/bmj.305.6865.1330","article-title":"Bovine gangliosides and acute motor polyneuropathy","volume":"305","author":"Figueras","year":"1992","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.phrs.2023.106967_bib8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.medcli.2013.02.021","article-title":"Risk of hypercalcemia and hipervitaminosis D induced by calcifediol. Review of cases reported to the Spanish Pharmacovigilance System","volume":"141","author":"Garc\u00eda Dolad\u00e9","year":"2013","journal-title":"Med. Clin. (Barc.)"},{"issue":"6","key":"10.1016\/j.phrs.2023.106967_bib9","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1517\/14740338.2015.1036857","article-title":"Dronedarone and renal impairment: evaluation of Spanish postmarketing reports and review of literature","volume":"14","author":"Tarapu\u00e9s","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.phrs.2023.106967_bib10","unstructured":"Royal Decree 577\/2013, of July 26, which regulates the pharmacovigilance of medicines for human use [Real Decreto 577\/2013, de 26 de julio, por el que se regula la farmacovigilancia de medicamentos de uso humano]. \u3008https:\/\/www.boe.es\/boe\/dias\/2013\/07\/27\/pdfs\/BOE-A-2013\u20138191.pdf\u3009."},{"issue":"1","key":"10.1016\/j.phrs.2023.106967_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40264-018-0766-8","article-title":"Towards drug safety surveillance and pharmacovigilance: current progress in detecting medication and adverse drug events from electronic health records","volume":"42","author":"Liu","year":"2019","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.phrs.2023.106967_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00002018-200932010-00007","article-title":"An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain","volume":"32","author":"Pedr\u00f3s","year":"2009","journal-title":"Drug Saf."},{"issue":"3","key":"10.1016\/j.phrs.2023.106967_bib13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00228-013-1630-5","article-title":"Prevalence, risk factors and main features of adverse drug reactions leading to hospital admission","volume":"70","author":"Pedr\u00f3s","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2023.106967_bib14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/clpt.2009.185","article-title":"A pharmacovigilance program from laboratory signals for the detection and reporting of serious adverse drug reactions in hospitalized patients","volume":"87","author":"Ramirez","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2023.106967_bib15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/cts.12526","article-title":"Clinical implementation of pharmacogenetic testing in a hospital of the Spanish National Health System: strategy and experience over 3 years","volume":"11","author":"Borobia","year":"2018","journal-title":"Clin. Transl. Sci."},{"issue":"17","key":"10.1016\/j.phrs.2023.106967_bib16","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.3390\/jcm10173772","article-title":"PriME-PGx: La Princesa University Hospital Multidisciplinary initiative for the implementation of pharmacogenetics","volume":"10","author":"Zubiaur","year":"2021","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.phrs.2023.106967_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.670945","article-title":"Adverse reactions to drugs of special interest in a pediatric oncohematology service","volume":"12","author":"Amaro-Hosey","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106967_bib18","article-title":"Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1\/PD-L1 inhibitors in real-world practice","volume":"9","author":"Sabat\u00e9 Gallego","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"issue":"3","key":"10.1016\/j.phrs.2023.106967_bib19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bcp.13471","article-title":"Drug-related deaths in hospital inpatients: a retrospective cohort study","volume":"84","author":"Montan\u00e9","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106967_bib20","series-title":"Pharmacoepidemiology \u2013 An introduction","article-title":"The contribution of epidemiology to the study of drug uses and effects","author":"Porta","year":"1988"},{"issue":"3","key":"10.1016\/j.phrs.2023.106967_bib21","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/bcp.13824","article-title":"Study design, process and outcome indicators of post-authorization studies aimed at evaluating the effectiveness of risk minimization measures in the EU PAS Register","volume":"85","author":"Farcas","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106967_bib22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/bmj.1.5905.440","article-title":"Regular aspirin intake and acute myocardial infarction","volume":"1","year":"1974","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.phrs.2023.106967_bib23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/pds.1171","article-title":"The history pf the drug utilization research group in Europe","volume":"15","author":"Bergman","year":"2005","journal-title":"Pharmacoepidemol. Drug Saf."},{"key":"10.1016\/j.phrs.2023.106967_bib24","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1258\/jrsm.2009.09k002","article-title":"Learning how to control biases in studies to identify adverse effects of drugs: a brief personal history","volume":"102","author":"Jick","year":"2009","journal-title":"J. R. Soc. Med."},{"issue":"15","key":"10.1016\/j.phrs.2023.106967_bib25","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1056\/NEJM197104222841604","article-title":"Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women","volume":"284","author":"Herbst","year":"1971","journal-title":"N. Engl. J. Med."},{"issue":"5599","key":"10.1016\/j.phrs.2023.106967_bib26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/bmj.2.5599.199","article-title":"Investigation of relation between use of oral contraceptives and thromboembolic disease","volume":"2","author":"Vessey","year":"1968","journal-title":"Br. Med J."},{"issue":"6271","key":"10.1016\/j.phrs.2023.106967_bib27","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1136\/bmj.282.6271.1216","article-title":"Postmarketing surveillance of adverse drug reactions in general practice. II: Prescription-event monitoring at the University of Southampton","volume":"282","author":"Inman","year":"1981","journal-title":"Br. Med. J. (Clin. Res. Ed. )"},{"key":"10.1016\/j.phrs.2023.106967_bib28","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1056\/NEJM197902013000502","article-title":"Replacement estrogens and endometrial cancer","volume":"300","author":"Jick","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2023.106967_bib29","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/bmj.302.6779.766","article-title":"Validation of the information recorded on general practitioner computerized data resource in the United Kingdom","volume":"302","author":"Jick","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2023.106967_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023090","article-title":"Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation","volume":"8","author":"Pacurariu","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.phrs.2023.106967_bib31","series-title":"Strom","article-title":"Pharmacoepidemiology","author":"Strom","year":"1989"},{"key":"10.1016\/j.phrs.2023.106967_bib32","unstructured":"A. G. Hartzema M. Porta Serra\u00a0In: H.H. Tilson (Ed.), Pharmacoepidemiology: an introduction 1988 Cincinnati."},{"issue":"8733","key":"10.1016\/j.phrs.2023.106967_bib33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0140-6736(91)90744-A","article-title":"Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti- inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding","volume":"337","author":"Laporte","year":"1991","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.phrs.2023.106967_bib34","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.1986.03380130077032","article-title":"A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study","volume":"256","author":"Risks of agranulocytosis and aplastic anemia","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2023.106967_bib35","series-title":"Principios de epidemiolog\u00eda del medicamento","author":"Laporte","year":"1983"},{"key":"10.1016\/j.phrs.2023.106967_bib36","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00001648-199311000-00004","article-title":"The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs","volume":"4","author":"P\u00e9rez-Gutthann","year":"1993","journal-title":"Epidemiology"},{"key":"10.1016\/j.phrs.2023.106967_bib37","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2125.1998.00701.x","article-title":"Use of the UK general practice research database for pharmacoepidemiology","volume":"45","author":"Garc\u00eda Rodr\u00edguez","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2023.106967_bib38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1365-2125.1999.00885.x","article-title":"Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs","volume":"47","author":"De Abajo","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106967_bib39","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.319.7217.1106","article-title":"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case- control study","volume":"319","author":"De Abajo","year":"1999","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.phrs.2023.106967_bib40","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0212-6567(02)79129-4","article-title":"El Proyecto BIFAP: Base de datos para la Investigaci\u00f3n Farmacoepidemiol\u00f3gica en Atenci\u00f3n Primaria [The BIFAP project: database for pharmaco-epidemiological research in primary care]","volume":"30","author":"Salvador Rosa","year":"2002","journal-title":"Aten. Prima"},{"key":"10.1016\/j.phrs.2023.106967_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1207976","article-title":"Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis","volume":"14","author":"Dur\u00e1n","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"31","key":"10.1016\/j.phrs.2023.106967_bib42","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1016\/j.vaccine.2021.06.029","article-title":"Papillomavirus vaccination and Guillain-Barre Syndrome among girls: a cohort study in Spain","volume":"39","author":"Mart\u00edn-Merino","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.phrs.2023.106967_bib43","doi-asserted-by":"crossref","first-page":"n1038","DOI":"10.1136\/bmj.n1038","article-title":"Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study","volume":"373","author":"Prats-Uribe","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2023.106967_bib44","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/ije\/dyz266","article-title":"Data resource profile: the valencia health system integrated database (VID)","volume":"49","author":"Garc\u00eda-Sempere","year":"2020","journal-title":"Int. J. Epidemiol."},{"issue":"10","key":"10.1016\/j.phrs.2023.106967_bib45","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/pds.5006","article-title":"BIFAP Team. Base de Datos para la Investigaci\u00f3n Farmacoepidemiol\u00f3gica en Atenci\u00f3n Primaria (BIFAP): A data resource for pharmacoepidemiology in Spain","volume":"29","author":"Maci\u00e1-Mart\u00ednez","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"6","key":"10.1016\/j.phrs.2023.106967_bib46","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1093\/ije\/dyac068","article-title":"Data resource profile: the information system for research in primary care (SIDIAP)","volume":"51","author":"Recalde","year":"2022","journal-title":"Int. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.phrs.2023.106967_bib47","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cpt.1833","article-title":"Working Group 3 of ENCePP (Inventory of EU data sources and methodological approaches for multisource studies). Different Strategies to Execute Multi-Database Studies for Medicines Surveillance in Real-World Setting: A Reflection on the European Model","volume":"108","author":"Gini","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.phrs.2023.106967_bib48","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/jamia\/ocac153","article-title":"The US Food and Drug Administration Sentinel System: a national resource for a learning health system","volume":"29","author":"Brown","year":"2022","journal-title":"J. Am. Med. Inf. Assoc."},{"issue":"1","key":"10.1016\/j.phrs.2023.106967_bib49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cpt.2476","article-title":"From Inception to ConcePTION: genesis of a network to support better monitoring and communication of medication safety during pregnancy and breastfeeding","volume":"111","author":"Thurin","year":"2022","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.phrs.2023.106967_bib50","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation \u2013 a framework for causal inference from observational studies","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2023.106967_bib51","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.phrs.2016.11.027","article-title":"Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS\/TEN are different from those found for the same AED-induced DRESS in the Spanish population","volume":"115","author":"Ram\u00edrez","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2023.106967_bib52","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1001\/jama.2012.136","article-title":"Health care cost and value","volume":"307","author":"McMahon","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2023.106967_bib53","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMp1011024","article-title":"What is value in health care?","volume":"363","author":"Porter","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2023.106967_bib54","first-page":"16576","article-title":"El valor de las innovaciones m\u00e9dicas","volume":"160","author":"Sacristan","year":"2019","journal-title":"Pap. Econ. Esp."},{"key":"10.1016\/j.phrs.2023.106967_bib55","series-title":"Methods for the Economic Evaluation Of Health Care Programmes","author":"Drummond","year":"2005"},{"issue":"2","key":"10.1016\/j.phrs.2023.106967_bib56","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.gaceta.2019.02.009","article-title":"Evaluation of new medicines in Spain and comparison with other European countries","volume":"34","author":"Epstein","year":"2020","journal-title":"Gac. Sanit."},{"key":"10.1016\/j.phrs.2023.106967_bib57","doi-asserted-by":"crossref","unstructured":"Zozaya N., Mart\u00ednez L., Alcal\u00e1 B., Hidalgo A. Evaluaci\u00f3n, financiaci\u00f3n y regulaci\u00f3n de los medicamentos innovadores en los pa\u00edses desarrollados. Fundaci\u00f3n Weber, 2018. Available at: \u3008https:\/\/weber.org.es\/wp-content\/uploads\/2017\/11\/interactivo_informe_evaluacion_financiacion_y_regulacion_de_los_medicamentos_innovadores_en_los_paises_desarrollado.pdf\u3009 (Accessed May 12, 2023).","DOI":"10.37666\/I3-2018"},{"issue":"3","key":"10.1016\/j.phrs.2023.106967_bib58","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00019053-199508030-00007","article-title":"Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation","volume":"8","author":"Rovira","year":"1995","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.phrs.2023.106967_bib59","unstructured":"Lobo F., Oliva J., Vida J. La evaluaci\u00f3n de la eficiencia de tecnolog\u00edas sanitarias en Espa\u00f1a: origen, evoluci\u00f3n y estado actual. Informe FUNCAS, septiembre de 2022. Available at \u3008https:\/\/www.funcas.es\/documentos_trabajo\/la-evaluacion-de-la-eficiencia-de-las-tecnologias-sanitarias-en-espana-origen-evolucion-y-estado-actual\/\u3009 (Accessed May 12, 2023)."},{"issue":"1","key":"10.1016\/j.phrs.2023.106967_bib60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jval.2019.06.012","article-title":"Economic evaluation for pricing and reimbursement of new drugs in Spain: fable or desideratum?","volume":"23","author":"Oliva-Moreno","year":"2020","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.phrs.2023.106967_bib61","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.aprim.2020.02.012","article-title":"Informes de posicionamiento terap\u00e9utico: experiencia en Espa\u00f1a en el periodo 2013-2019 [Therapeutic positioning reports: experience in Spain during the period 2013-2019]","volume":"52","author":"Garc\u00eda","year":"2020","journal-title":"Aten. Prima"},{"key":"10.1016\/j.phrs.2023.106967_bib62","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.gaceta.2019.06.007","article-title":"\u00bfQu\u00e9 es una intervenci\u00f3n sanitaria eficiente en Espa\u00f1a en 2020? [What is an efficient health intervention in Spain in 2020?]","volume":"34","author":"Sacrist\u00e1n","year":"2020","journal-title":"Gac. Sanit."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823003237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823003237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:51:27Z","timestamp":1760914287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661823003237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":62,"alternative-id":["S1043661823003237"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106967","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical pharmacology facing the real-world setting: Pharmacovigilance, pharmacoepidemiology and the economic evaluation of drugs","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106967","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106967"}}